Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Pfizer
Essen Biotech
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
OncoNano Medicine, Inc.
Turning Point Therapeutics, Inc.
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Antengene Corporation
IGM Biosciences, Inc.
Cedars-Sinai Medical Center
BPGbio
Edwards Lifesciences
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Cedars-Sinai Medical Center
Synlogic
OHSU Knight Cancer Institute
TopAlliance Biosciences
Rutgers, The State University of New Jersey
Innovent Biologics (Suzhou) Co. Ltd.
Chinese PLA General Hospital
Shanghai Henlius Biotech
Symphogen A/S
Seagen Inc.
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Symphogen A/S
Celgene
Menarini Group
Northwestern University
Chinese PLA General Hospital
Amgen
Symphogen A/S
M.D. Anderson Cancer Center
Incyte Corporation
Eli Lilly and Company
Eli Lilly and Company
Northwestern University
Chinese PLA General Hospital
Amgen
Incyte Corporation
Edwards Lifesciences
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Verastem, Inc.